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Abstract
Follicular dendritic cell (FDC) sarcomas are rare mesenchymal
tumors with variable clinical, morphologic, and phenotypic char-
acteristics. Transcriptome analysis was performed on multiple
FDC sarcomas and compared with other mesenchymal tumors,
microdissected Castleman FDCs, and normal ﬁbroblasts. Using
unsupervised analysis, FDC sarcomas clustered with microdis-
sected FDCs, distinct from other mesenchymal tumors and ﬁbro-
blasts. The speciﬁc endowment of FDC-related gene expression
programs in FDC sarcomas emerged by applying a gene signature
of differentially expressed genes (n ¼ 1,289) between microdis-
sected FDCs and ﬁbroblasts. Supervised analysis comparing FDC
sarcomas with microdissected FDCs and other mesenchymal
tumors identiﬁed 370 and 2,927 differentially expressed tran-
scripts, respectively, and on the basis of pathway enrichment
analysis ascribed to signal transduction, chromatin organization,
and extracellular matrix organization programs. As the transcrip-
tomeof FDC sarcomas retained similaritywith FDCs, the immune
landscape of FDC sarcoma was investigated by applying the
CIBERSORT algorithm to FDC sarcomas and non-FDC mesen-
chymal tumors and demonstrated that FDC sarcomas were
enriched in T follicular helper (TFH) and T regulatory (TREG) cell
populations, as conﬁrmed in situ by immunohistochemistry. The
enrichment in speciﬁc T-cell subsets prompted investigating the
mRNA expression of the inhibitory immune receptor PD-1 and its
ligands PD-L1 and PD-L2, which were found to be signiﬁcantly
upregulated in FDC sarcomas as compared with other mesenchy-
mal tumors, a ﬁnding also conﬁrmed in situ. Here, it is demon-
strated for the ﬁrst time the transcriptional relationship of FDC
sarcomas with nonmalignant FDCs and their distinction from
other mesenchymal tumors.
Implications: The current study provides evidence of a peculiar
immune microenvironment associated with FDC sarcomas that
may have clinical utility.Mol Cancer Res; 15(5); 541–52.2017 AACR.
Introduction
Follicular dendritic cell (FDC) sarcomas are rare malignancies
ﬁrst described by Monda and colleagues (1), characterized by a
rather variable clinical presentation and a high degree of mor-
phologic and immunophenotypical heterogeneity (2). FDC sar-
coma presents with lymph node disease in 31% of cases, extra-
nodal disease in 58%, and both nodal and extranodal disease in
10% (3). Cervical nodes are most often affected in nodal presen-
tation. A wide variety of extranodal sites can be affected, most
commonly tonsil, gastrointestinal tract, soft tissue, mediastinum,
retroperitoneum, omentum, skin, and lung (4). The clinical
behavior is generally indolent with nearly 10% of patients dying
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of the disease; however, local recurrence is frequent (around 40%
of cases) and cases displaying an aggressive pace have been
reported (5). Moreover, as most studies on this rare entity consist
of anecdotal reports, no standard of treatment has been so far
identiﬁed (6).
An insight into the pathogenesis of FDC sarcomas is deﬁ-
nitely lacking. A minority of cases occur in association with the
hyaline vascular type of Castleman disease or in the setting of
dysregulated immune responses related with Epstein-Barr virus
(EBV) infections and inﬂammatory diseases, such as inﬂam-
matory pseudo-tumors, which suggest that FDC hyperplasia
may represent a priming condition (7). FDC sarcomas are
characterized by the proliferation of spindle-to-oval cells with
mild nuclear atypia, which may also comprise epithelioid and/
or multinucleated elements (8). Malignant cells usually grow
cohesively being aggregated in fascicles and whorls that may be
reminiscent of meningioma growth pattern and show a low
number of mitotic ﬁgures (1–5/10 high-power ﬁelds). How-
ever, cases with frank cytological atypia, foci of necrosis, and a
high mitotic count can be observed, usually corresponding to
intra-abdominal masses measuring more than 6 cm and being
characterized by a more aggressive clinical course (9). More-
over, a considerable variability is observed in the density and
contexture of lymphoid and other immune elements accom-
panying the malignant proliferation, and no consistent attempt
has been so far made in characterizing the FDC sarcoma–
associated immune microenvironment (2).
Besides the expression ofmesenchymal cell markers, most FDC
sarcomas display signs of an FDC immunophenotype with fre-
quent expression of CD21, CD23, CD35, clusterin, Ki-M4P,
Claudin 4, and CXCL13 (10). Yet, one or more of such FDC
markers can be lost, which may render the differential diagnosis
with other sarcomas problematic, warranting testing multiple
FDC markers (11). Although a histogenetic afﬁnity to FDC can
be argued in these sarcomas based on morphologic and immu-
nophenotypical cues and on the reporting of folliculocentric B
lymphocyte–rich morphologic presentations (12), no molecular
evidence has been so far provided that could support the prefer-
ential representation of FDC transcriptional landscape in com-
parisonwith othermesenchymal tumors andhighlight themolec-
ular programs characteristic of FDC sarcomas.
In this study, we investigated for theﬁrst time the transcriptome
of FDC sarcomas and compared itwith that of othermesenchymal
tumor histotypes.
We demonstrated that on unsupervised cluster analysis, FDC
sarcomas are histogenetically linked with FDC and display a
peculiar transcriptional proﬁle that signiﬁcantly diverges from
that of other mesenchymal tumors. Moreover, through the
application of the CIBERSORT method (13), we could gain
insight into the immune microenvironment of FDC sarcomas
and highlight a preferential enrichment in the transcriptional
programs of follicular helper T cells (TFH) and regulatory T cells
(TREG) lymphoid subsets.
Materials and Methods
Case collection
Formalin-ﬁxed and parafﬁn-embedded tissue (FFPE) samples
were selected from the archives of the Pathology Units in Frank-
furt, Bologna, Brescia, Bombay, Barcelona, Lisbon, and Vienna.
These included 29 surgically resected FDC sarcomas and 32 cases
of soft-tissue tumors. Among soft-tissue tumors, histotypes with
ﬁbroblastic/myoﬁbroblastic differentiation were selected on the
basis of their chance to display transcriptional and phenotypic
overlaps with FDC sarcomas, whereas cases with myogenic,
adipocytic, chondro-osseous, or neural differentiation were
excluded. In details, 3 cases of desmoid-type ﬁbromatosis, 8 cases
of dermatoﬁbrosarcoma protuberans, 3 low-grade ﬁbromyxoid
sarcomas, 6 inﬂammatory myoﬁbroblastic tumors (4 ALKþ, 2
ALK), and 12 solitary ﬁbrous tumors (including 3 cases diag-
nosed as hemangiopericytomas) were selected. For control pur-
poses, 5 samples of laser microdissected FDCs from regressive
germinal centers of HIV-negative hyaline-vascular Castleman
disease were adopted. Furthermore, 3 samples of ﬁbroblasts,
obtained from routine circumcisions and subsequently FFPE,
were included in the gene expression proﬁling. Samples' char-
acteristics are summarized in Supplementary Table S1.
All FDC sarcoma cases were stained for the FDC markers
CD21, CD23, CD35, clusterin, and CXCL13, and diagnoses
were conﬁrmed by expert pathologists in a panel session at
a multi-head microscope (C. Agostinelli, F. Facchetti, M.-L.
Hansmann, S. Hartmann, and S.A. Pileri).
RNA extraction and gene expression proﬁle generation
RecoverAll Total Nucleic Acid Isolation Kit (Ambion, Life
Technologies) was used to extract total RNA from FFPE tissues
according to the manufacturer's procedure. RNA was quantiﬁed
using ND-1000 spectrophotometer running software version
3.0.1 (NanoDrop Technologies, Inc.). After RNA extraction from
samples, the Illumina Whole Genome cDNA–mediated Anneal-
ing, Selection, extension, and Ligation (DASL) assay was adopted,
which allowed for efﬁcient expression proﬁling of partially
degraded RNA from FFPE samples.
In details, the whole-genome DASL assay begins with the
conversion of total RNA to cDNA using biotinylated oligo
(dT) and random nonamer primers. The biotinylated cDNA is
then annealed to the DASL assay pool (DAP) probe groups
that contain oligonucleotides speciﬁcally designed to interro-
gate each target sequence in the transcripts. The probes span
about 50 bases, making it possible to proﬁle partially degrad-
ed RNA. Correctly annealed, assay-speciﬁc oligos are subse-
quently extended and ligated to generate ampliﬁable pro-
ducts. These templates are labeled during PCR ampliﬁcation
by including ﬂuorescent primers in the reaction. The resulting
PCR products are scanned using the BeadArray Reader or
iScan System to determine the presence or absence of speciﬁc
genes (14–17).
Immunohistochemistry
Immunohistochemistry (IHC)wasperformedusing apolymer-
based detection method. Four-micrometers-thick tissue sections
were deparafﬁnized and rehydrated. The antigen unmasking was
performed using Epitope Retrieval Solutions (Novocastra) at
pH6, pH9, and pH8 in a PT Link Dako pretreatment module at
98C for 30 minutes. Subsequently, the sections were brought to
room temperature and washed in PBS. After neutralization of the
endogenous peroxidase with 3% H2O2 for 10 minutes and Fc
blocking by a speciﬁc protein block for 8 minutes, the samples
were incubated overnight with themonoclonal anti-human PD-1
(Clone NAT105; 1/50 pH8 Abcam 52587), polyclonal anti-
human CD274/PDL-1 (1/400 pH9 Acris Antibodies AP
30655PU-N), polyclonal anti-human CD273/PDL-2 (1/400 pH8
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Acris Antibodies AP30656PU-N), or monoclonal anti-human
Foxp3 (Clone 236A/E7; 1/100 pH9 Abcam 20034) antibodies
at 4C.
Staining was revealed by polymer detection kit (Novolink
Polymer Detection System Novocastra) using the substrate chro-
mogen 3,30-diaminobenzidine (DAB).
IHC for multiple marker detection was performed by 2
sequential rounds of single-marker IHC. In details, the tissue
samples were incubated ﬁrst with the monoclonal anti-human
BCL-6 (Clone LN22; 1:100, pH 9, Leica Biosystems Newcastle
Ltd.) antibody, with which binding was revealed by polymer
detection kit DAB, and secondly, after Fc blocking, with the
polyclonal anti-human CD3 (1:100, pH 9, Abcam 5690) anti-
body revealed by streptavidin-biotin kit (Dako LSABþ System-
AP) using Ferangi Blue chromogen (Biocare Medical Cat. Num.
FB813).
All the slides were counterstained with Harris hematoxylin
(Novocastra). The sections were analyzed under a Zeiss AXIO
Scope A1 optical microscope (Zeiss Oberkochen), and micro-
photographs were collected using a Zeiss Axiocam 503 Color
(Zeiss).
For the comparative analysis of PD-L1 expression among
different FDC sarcoma and mesenchymal tumor cases, tissue
microarrays (TMA) were constructed, which comprised tumor
cell–enriched cores (3 cores per case, 1 mm in diameter) from
22 FDC sarcomas and 27 mesenchymal tumors, which, for
control purposes, contained also examples of ﬁbrosarcoma and
leiomyosarcoma besides the histotypes object of the transcrip-
tional analysis. TMA slides were evaluated in a blinded fashion
by 2 experienced pathologists (F. Fuligni and L. Lorenzi)
according to an ad-hoc score combining the percentage of
positive tumor cells and the intensity of the staining detailed
in the Supplementary File.
Data analysis
The raw data were uploaded in BRB-Array Tools (Version
4.4.1; ref. 18) for normalization and supervised analysis. Unsu-
pervised analyses by hierarchical clustering, principal compo-
nent analysis (PCA), and non-negative matrix factorization
(NMF) algorithms were carried out using MeV v4.7.4 (19) and
were applied to identify a group of cases from pathologically
deﬁned entities.
To extend the comparison of FDC sarcoma transcriptional
programs with a normal mesenchymal cell counterpart other
than ﬁbroblasts, we included a published gene expression proﬁle
dataset (20) of mesenchymal stem cells (MSC) GSE28205
(GSM698427, GSM698433, GSM698437, GSM698439) for
unsupervised hierarchical clustering analysis. In these analyses,
the combatmethodwasused to correct batch effects on expression
values and to reduce the variability across different microarray
experiments (21).
Supervised analyses with SAM (22) and gene set enrichment
analysis (GSEA software; ref. 23) were used to identify genes and
pathways/signatures associated with FDC sarcoma.
ConsensusPathDB–human interaction database (http://www.
consensuspathdb.org; ref. 24) was used to deﬁne pathway and
functional categories for a gene list annotation.
EASE softwarewas applied to establish the biologic processes of
gene signatures differentiating FDC sarcomas from microdis-
sected FDCs and non-FDCmesenchymal tumors, deﬁned accord-
ing to gene ontology (25–27).
To investigate the inﬁltrating immune cell landscape of FDC
sarcomas and compare it with that of other mesenchymal
tumors, we applied CIBERSORT computational method to the
gene expression proﬁle data, which accurately quantiﬁes the
relative levels of distinct cell types within a complex gene
expression mixture. The raw intensity values of our samples
(deﬁned as mixture ﬁle) were compared to LM22 gene signature
ﬁle consisting of 547 genes that distinguish 22 mature human
hematopoietic populations [T-cell susbets, na€ve andmemory B
cells, plasma cells, natural killer (NK) cells, and myeloid cell
subsets] supplied by CIBERSORT tool. The following metrics
were adopted: quantile normalization, permutations parameter
¼ 1,000, P  0.05 threshold of the deconvolution across all cell
subsets (13).
The Student t test was used on normalized and log2-trans-
formed intensity value to evaluate the different mRNA expression
levels of PD-1, PD-L1, and PD-L2 in FDC sarcomas and other
mesenchymal tumors.
The microarray data have been deposited in NCBI's Gene
Expression Omnibus (GEO) and are accessible through GEO
series accession number GSE90592. More data analysis details
and any associated reference are available in the Supplementary
File.
Results
FDC sarcomas have a distinct FDC-related transcriptional
proﬁle which allows differentiation from other mesenchymal
tumors
We ﬁrst adopted an unsupervised hierarchical clustering
approach to determine whether the transcriptional proﬁle of the
29 FDC sarcomas had signiﬁcant overlap with that of
other mesenchymal tumors, which encompassed 3 cases of des-
moid-type ﬁbromatosis, 8 cases of dermatoﬁbrosarcoma protu-
berans, 3 low-grade ﬁbromyxoid sarcomas, 6 inﬂammatory myo-
ﬁbroblastic tumors (4 ALKþ, 2 ALK), and 12 solitary ﬁbrous
tumors (including 3 cases diagnosed as hemangiopericytomas).
Within the same unsupervised clustering analysis, we
assessed the relationship among the transcriptional proﬁle of
FDC sarcomas and that of microdissected FDCs from 5 Castle-
man disease cases and 3 FFPE ﬁbroblast samples. FDC sarcoma
sample proﬁles clustered together with those of microdissected
Castleman FDCs and separately from those of other mesen-
chymal tumors, which clustered together with ﬁbroblast pro-
ﬁles (Fig. 1A).
Three-dimension PCA revealed that FDC sarcoma cases formed
a distinct cloud from other mesenchymal tumors, the percentage
of variance explained by the main 3 components being 42.6%
(Fig. 1B).
To assess the stability of hierarchical clustering, NMF was
run by the use of different number of clusters (range, 2–8) and
the optimum number of clusters was determined for k ¼ 2 and
cophenetic coefﬁcient ¼ 0.991. Two major clusters (one
including FDC sarcomas and microdissected Castleman FDCs
and the other including non-FDC mesenchymal tumors and
ﬁbroblast samples) generated by hierarchical clustering algo-
rithm were conﬁrmed also using NMF method (Supplementary
Fig. S1).
These results suggested that FDC sarcoma transcriptional pro-
ﬁle was different from that of other mesenchymal neoplasms
being correlated with that of FDCs.
Gene Proﬁling of FDC Sarcomas
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To evaluate whether signiﬁcant transcriptional heterogeneity
could be detected among the 29 FDC sarcoma samples, we
performed unsupervised hierarchical clustering analysis, which
identiﬁed 2 major groups (Supplementary Fig. S2A). When
these 2 groups were compared by applying SAM supervised
analysis [false discovery rate (FDR) < 0.01, fold change (FC) 
2], only 20 genes were found to be differentially expressed,
indicating a low degree of transcriptional heterogeneity within
the FDC sarcoma group (Supplementary Fig. S2B). To further
verify that the divergences in the transcriptional proﬁle of FDC
sarcomas and non-FDC mesenchymal tumors were dictated by
the representation of FDC-related transcriptional programs
rather than stemming from the heterogeneity in tumor local-
ization and overall environment, we compared the transcrip-
tional proﬁles of microdissected FDCs with that of ﬁbroblast
samples by supervised analysis and adopted the differentially
expressed gene signature to perform an unsupervised hierar-
chical clustering of FDC sarcomas and other mesenchymal
tumors. SAM algorithm (FDR  0.001, FC  2) identiﬁed
neatly separated proﬁles of microdissected FDCs and ﬁbroblast
samples, with 1,289 genes differentially expressed (777 genes
upregulated and 512 genes downregulated in FDCs; Supple-
mentary Fig. S3 and Table S2).
When such a signature was applied to FDC sarcomas and non-
FDC mesenchymal tumors by hierarchical clustering approach,
the FDC sarcomas were robustly separated from other mesenchy-
mal tumor samples (Fig. 2A). Consistently, GSEA revealed a
signiﬁcant enrichment in the genes differentially modulated
between microdissected FDCs and ﬁbroblasts in the FDC sarco-
mas cohort (P < 0.00001, Fig. 2B).
As sarcomas generally derive from mesenchymal precursor/
stem cells, to further conﬁrm the speciﬁc transcriptional relation-
ship between the FDC sarcomas and microdissected FDCs, unsu-
pervised hierarchical clustering analysis was performed including
in silicoproﬁles ofMSCs.Weobserved thatMSCs cluster separately
from FDCs and FDC sarcomas, closely to normal ﬁbroblasts and
sharing transcriptional features with ﬁbroblasts and non-FDC
mesenchymal tumors (Supplementary Fig. S4). This further sup-
ports our hypothesis that FDC sarcoma signature differs from the
one of neoplastic mesenchymal cells as well as from that of
normal mesenchymal cells, at both the stem cell level and termi-
nal step of differentiation.
FB
MTs
FDCS FDCSCD-FDCs
–60–40–20
2040
40
20
0
–20
–60 –40 –20 0 20 40 60
0
PC1
PC2
A
B
–7 0 8.2
PC3
Figure 1.
Unsupervised analysis (1,683 genes). A, Hierarchical clustering comparing FDC sarcomas, microdissected Castleman FDCs, other mesenchymal sarcomas, and
ﬁbroblasts. In thematrix, each row represents a gene and each column represents a sample. The color scale illustrates the relative expression level of a gene across all
samples: red represents an expression level above the mean and green represents expression lower than the mean. B, PCA plot shows to which extent the different
biologic samples group together. In particular, the percentage of variance explainedby the 3main componentswas 42.65% (component 1, x-axis: 25.36%; component
2, y-axis: 11.56%; and component 3, z-axis: 5.73%). FDC sarcomas (FDCS), green; microdissected Castleman FDCs (CD-FDCs), yellow; ﬁbroblast (FB), purple; other
nesenchymal tumors (MTs): desmoid-type ﬁbromatosis (DF), blue; dermatoﬁbrosarcomas protuberans (DFSP), red; ﬁbromyxoid sarcomas (FMS), sky blue,
inﬂammatory myoﬁbroblastic tumors (IM ALKþ and IM ALK), black; solitary ﬁbrous tumors (SF), gray, hemangiopericytomas (HP), orange.
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These results indicate that the transcriptional proﬁle of FDC
sarcomas, which differs from that of other mesenchymal tumor
histotypes, is contributed by FDC-related programs over mesen-
chymal cell ones.
The transcriptome of FDC sarcomas is characterized by the
deregulation of signal transduction and cell cycle, chromatin
organization, extracellular matrix organization, and
metabolism pathways.
On the basis of the demonstration that FDC sarcomas dis-
played a transcriptional proﬁle distinct from that of other mes-
enchymal tumors, we focused on analyzing the pathways that
were differentially represented in FDC sarcomas in comparison
with microdissected Castleman FDCs and with non-FDC mesen-
chymal tumors, which were likely to reﬂect the core deregulated
programs of these rare malignancies.
On SAM supervised analysis (FDR < 0.1, FC  2), 370 genes
distinguished FDC sarcomas from microdissected FDCs (Sup-
plementary Fig. S5A). Of these genes, 64 were signiﬁcantly
upregulated in FDC sarcomas whereas the remaining 306 were
downregulated (Supplementary Table S3). When pathway
enrichment analysis was performed on differentially expressed
genes between FDC sarcomas and microdissected FDCs by the
ConsensusPathDB (Reactome pathway data sets, P value cutoff
¼ 0.0001), the most represented pathways were those of signal
transduction and cell cycle, chromatin organization, and metabolism
(Supplementary Table S4). Moreover, a signiﬁcant enrichment
also emerged in genes belonging to the immune system path-
way even if the comparison between FDC sarcomas and micro-
dissected Castleman FDCs implied a potentially different con-
tribution of inﬁltrating immune elements in the 2 sample
groups.
Other Mesenchymal Tumors FDC SarcomasA
B
Gene signature differentially expressed between FDCs vs. Fibroblast
P < 0.00001
–5.5          0              5.7
Figure 2.
Differentially expressed gene signature (1,289 genes) between microdissected FDCs and ﬁbroblast samples was applied to FDC sarcomas and other mesenchymal
tumors by (A) hierarchical clustering algorithm that demonstrated a distinct cluster of FDC sarcomas from other mesenchymal tumors. In the matrix,
each row represents a gene and each column represents a sample. The color scale illustrates the relative expression level of a gene across all samples: red represents
an expression level above themean and green represents expression lower than themean.B,GSEA revealed signiﬁcant enrichment of genes up- or downregulated in
microdissected FDCs respect to ﬁbroblast in FDC sarcoma. The enrichment score curve was obtained from GSEA software. In the enrichment plot, the x-axis
shows the rank order of genes from the most upregulated to the most downregulated between microdissected FDC and ﬁbroblast samples. Vertical black line
indicates the position of the enriched genes (Hit) comprising the gene set. The graph on the bottom shows the ranked list metric (signal-to-noise ratio) for
each gene as a function of the rank in the ordered dataset.
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Following the identiﬁcation of the transcriptional pathways
modulated between FDC sarcomas and microdissected FDCs, a
detailed analysis of the genes contributing to each pathway was
performed to assess whether the differentially represented path-
ways were contributed by genes with high degree of overlap
among the different pathways or whether groups of genes
speciﬁc for each pathway could be identiﬁed. Among the
differentially expressed genes contributing to the enriched
pathways, 85 proved to be selectively involved in one single
pathway (Fig. 3A), which substantiated that the deregulation of
the above mentioned molecular programs was rather speciﬁc
being not ascribable to genes with high redundancy among
Figure 3.
Venn diagrams of the 5 most represented pathways to deﬁne unique genes in the 2 different signatures. A, Eighty-ﬁve genes contributing to each pathway
modulated in FDC sarcomas versus microdissected FDCs. B, A total of 156 genes contributing to each pathway modulated in FDC sarcomas versus other
mesenchymal tumors.
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different programs. Of note, among the signiﬁcantly down-
regulated genes between FDC sarcomas and microdissected
FDCs were included genes reported to be target of loss-of-
function mutations on targeted genomic sequencing (28),
which belonged to the NF-kB and cell-cycle regulatory path-
ways (Supplementary Table S5).
We subsequently focused on the 2,927 differentially
expressed transcripts between FDC sarcomas and other mesen-
chymal sarcomas (2,041 upregulated and 886 downregulated
in FDC sarcomas) by the SAM analysis (FDR < 0.0001, FC  2;
Supplementary Fig. S5B and Table S6) and investigated the
differentially regulated transcriptional pathways (Reactome
pathway data sets, P value cutoff ¼ 0.0001). The programs that
were differentially represented in FDC sarcomas in comparison
with other mesenchymal tumors were those related to signal
transduction, cell cycle, metabolism, extracellular matrix organiza-
tion, and immune system (Supplementary Table S7). As for the
pathways differentially regulated between FDC sarcomas and
microdissected FDCs, those emerging from the comparison of
the transcriptional proﬁles of FDC sarcomas and other mesen-
chymal tumors featured 156 differentially expressed genes that
were selectively involved in one single pathway, further sub-
stantiating the speciﬁcity of such deregulated programs in FDC
sarcomas (Fig. 3B). Indeed, the modulated pathways emerging
from the comparison between FDC sarcomas and microdis-
sected FDCs largely overlapped with those differentially mod-
ulated between FDC sarcomas and non-FDC mesenchymal
tumors, with chromatin remodeling and extracellular matrix orga-
nization pathways resulting selectively involved in the former
and in the latter differentiation, respectively. Consistently, 116
genes were shared by the signatures differentiating FDC sarco-
mas from microdissected FDCs and non-FDC mesenchymal
tumors. We then applied EASE software to establish whether
speciﬁc biologic processes, deﬁned according to Gene Ontology
database, were signiﬁcantly represented among these 116 genes.
We found that, for the most part, they corresponded to biologic
processes such as chromatin assembly/disassembly, cell growth
and maintenance, intracellular signaling cascade, CDK activity,
and cell proliferation (Supplementary Table S8).
Overall, these results identify the gene sets and the relative
molecular pathways discriminating FDC sarcomas from nonma-
lignant FDCs and from other mesenchymal tumors and provide
new insight into FDC sarcoma pathobiology.
The immune landscape of FDC sarcomas is skewed toward TFH
and TREG enrichment and endowedwith PD-1 and PD-L1/2 axis
expression
FDCshave aprime role in themesenchymal organization of the
germinal center, which represents a highly dynamic microenvi-
ronment where specialized immune cell subsets including B cells,
TFH, TREG, macrophages, and myeloid dendritic cells undertake
interactions toward antibody afﬁnity maturation (29). As we
demonstrated that the transcriptional proﬁle of FDC sarcomas
retained congruity with that of FDCs while clearly differentiating
from that of ﬁbroblasts and non-FDC mesenchymal tumors, we
investigated the inﬁltrating immune cell landscape of FDC sar-
comas and compared itwith that of othermesenchymal tumors in
the attempt to identify clues about the enrichment in speciﬁc
immune cell populations. To this end,we applied theCIBERSORT
analysis method to the gene expression proﬁles of FDC sarcomas
and non-FDC mesenchymal tumors, which allowed a detailed
enumeration of immune cell subsets from the transcriptional
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proﬁles. On CIBERSORT analysis, a different proﬁle of immune
cell populations emerged between FDC sarcomas and other
mesenchymal tumors (Fig. 4A). Notably, FDC sarcomas proved
to be signiﬁcantly enriched in TFH and TREG, 2 populations
functionally related with the germinal center microenvironment,
and the actual presence of TFH and TREG cells within FDC sarcoma
samples was also conﬁrmed in situ by IHC analysis for BCL6/CD3
and Foxp3 (Fig. 4B). CIBERSORT analysis highlighted signiﬁcant
differences also in terms of cytotoxic T cells and NK cells that
was enriched in FDC sarcoma samples and of plasma cells, which
were more represented within the other mesenchymal tumor
histotypes.
The consistent enrichment in speciﬁc T-cell subsets prompted
us to investigate the mRNA expression level of the inhibitory
immune checkpoint molecule PD-1 and of its ligands PD-L1
and PD-L2 that constitute a pivotal axis in the regulation of
adaptive antitumor immunity within the tumor microenviron-
ment (30). The inhibitory checkpoint receptor PD-1 is
expressed on activated effector T and NK cells as a regulatory
feedback inducing their functional exhaustion and represents a
phenotypic marker of TFH and TREG cells correlated with the
activation status (31–33). In keeping with a higher frequency of
inﬁltrating TFH, TREG, and cytotoxic elements, PD-1 mRNA
expression levels proved to be signiﬁcantly higher in FDC
sarcoma samples than in the other mesenchymal tumors tested
(P ¼ 0.013; Fig. 5A), and the same trend was observed for the
PD-L1 and PD-L2 ligands (P ¼ 0.00024, P ¼ 0.00019,
respectively; Fig. 5B and C). The presence of PD-1–expressing
tumor-inﬁltrating lymphocytes in FDC sarcomas was detected
in situ by IHC as well as the expression of PD-L1 and PD-L2 by
malignant elements and inﬁltrating immune cells (Fig. 5D).
Within the FDC sarcoma group, we also investigated the cor-
relation between the expression of PD-1 and the frequency of
cytotoxic T cells, TFH, TREG, and NK cells, as determined by
CIBERSORT analysis, to assess whether one or more of these
cell subsets could be identiﬁed as predominant determinant(s)
of PD-1 expression levels. No signiﬁcant correlation was iden-
tiﬁed between PD-1 mRNA expression levels and the frequency
of any of the differentially enriched cell populations (not
shown), which implicated the contribution of diversiﬁed
tumor-inﬁltrating lymphocyte populations to PD-1 mRNA
expression within the FDC sarcoma microenvironment. More-
over, no signiﬁcant correlation could be identiﬁed between PD-
1 mRNA expression levels and those of the PD-1 ligands (not
shown), possibly owing to the higher variation of PD-1 expres-
sion as compared with that of the ligands among different FDC
sarcoma samples and to the puzzling effect of the PD-1 ligand
expression in the inﬁltrating immune cells. Indeed, the consis-
tent expression of PD-1 ligand among the different FDC sar-
coma cases also emerged at the protein level by extending IHC
analysis on TMAs constructed from 22 FDC sarcoma and 27
mesenchymal tumor samples. Tumor cell–enriched cores from
FDC sarcomas showed conspicuous reactivity for PD-L1 in
more than 60% of cases whereas cores from other mesenchymal
tumors displayed detectable PD-L1 in only 4% of cases (Fig. 5E;
Supplementary table S9).
These results indicate that FDC sarcomas have a peculiar
immunological microenvironment that is contributed by
functionally specialized T-cell populations, namely TFH and
TREG, and that can fall under the inﬂuence of the PD-1 and
PD-L1/2 axis.
Discussion
Along their malignant transformation, mesenchymal cells
may display variable signs of differentiation toward one lineage
while retaining considerable plasticity (34). The correspon-
dence between the expression or the disruption of speciﬁc
transcriptional programs and the acquisition or maintenance
of a speciﬁc functional phenotype has been poorly investigated.
FDCs are highly specialized reputed mesenchymal cells which
differentiate from perivascular mesenchymal precursors under
the driving stimuli of lymphoid tissue inducer cells, lympho-
toxins, and other cytokines (35). The acquisition of the FDC
phenotype is characterized by the expression of molecules
involved in the organization of the peculiar matricellular and
adhesive milieu of the germinal center, which includes type-I
collagen, SPARC, ICAM-1, VCAM-1, and MAdCAM-1, and ﬁnds
commonality in presumed mesenchymal elements of other
specialized microenvironments such as those of the bone
marrow hematopoietic niche (36). Moreover, FDC phenotypic
speciﬁcation is associated with the expression of functional
mediators of B-cell chemoattraction (i.e., CXCL-13), tropism
(BAFF, IL6), co-stimulation (C4bBP, iC3b/C3dg), and immune
complex trapping (CD21, CD35, CD23). In FDC sarcomas,
features of the FDC phenotype can be maintained, although
clones may present a high degree of heterogeneity as far as the
expression of FDC-related markers is concerned (11). We found
that sarcomatous transformation of FDCs is characterized by
the maintenance of FDC-related transcriptional programs as
suggested by the clustering of FDC sarcoma cases with micro-
dissected FDCs and by the successful differentiation of FDC
sarcomas from other mesenchymal tumors according to the
application of a differential signature obtained from the com-
parison between FDCs and ﬁbroblasts. This evidence implied
that FDC-related programs were prevalent over those resulting
from a common reputed mesenchymal origin in deﬁning FDC
sarcoma identity. From the attempt to identify the motifs of the
transcriptional deregulation occurring in sarcomatous FDCs as
compared with their nonmalignant counterpart, we derived
evidence of a prevalent downmodulation of transcriptional
networks involved in cell-cycle regulation, chromatin organi-
zation, and signal transduction, which included transcripts of
genes directly involved in or correlated with the FDC sarcoma
mutational landscape, such as NF-kB transcriptional targets
and cyclin-dependent kinase regulators (28). From these
results, the abating of regulatory fringes in key cellular pro-
grams rather than the forcing pressure of a speciﬁc oncogenic
pathway emerges as the transcriptional imprint of FDC malig-
nant phenotype. In the comparison between the gene expres-
sion proﬁle of FDC sarcomas and that of other mesenchymal
tumors, the same pathways were complemented by extracellu-
lar matrix and immune system molecular programs, which
underlined the association of FDC clones with a distinct extra-
cellular matrix and immunologic contexture consistent with
preserved FDC functional differentiation. On this respect, our
ﬁndings did not support the dichotomy of FDC sarcomas
recently emerged from miRNA proﬁling (37), suggesting the
existence of 2 distinct FDC sarcoma groups closer to ﬁbroblasts/
myopericytic tumors and Castleman microdissected FDCs,
respectively. Indeed, on transcriptional proﬁling, all the FDC
sarcoma cases clustered together with Castleman disease–
microdissected FDCs remaining clearly distinct from ﬁbroblasts
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and other mesenchymal tumors and displayed a low degree of
transcriptional heterogeneity. This apparent discrepancy
should be considered in the light of miRNA and mRNA proﬁles
reﬂecting different levels of information in cancer. Indeed,
miRNA proﬁles, as expression of regulatory networks tightly
linked with cell identity, can be efﬁciently adopted to infer
information related with the cell/tissue of origin even in the
case of profoundly depressed functional differentiation, such as
in poorly differentiated cancers (38), whereas mRNA proﬁles
are better reﬂective of the actual differentiation status mirroring
the transcriptional activity (39). Because of their function in
epigenetic regulation of cell processes, miRNA proﬁles can
therefore display considerable variability among individual
cases even in the presence of a rather homogeneous transcrip-
tional proﬁle.
Application of the CIBERSORT method for the enumeration
of inﬁltrating immune cell fractions from gene expression
proﬁles revealed the enrichment in TFH and TREG populations
in FDC sarcomas, which was also corroborated by in situ IHC
analyses. TFH cells are a specialized T-cell subset providing
growth and differentiation support to B cells of the germinal
center toward the establishment of antibody-mediated
immune responses (40). Controlled by the synergic activity
of TH and germinal center–related transcription factors, TFH are
essential for the germinal center cellular networking (41), the
impairment of their function resulting in defective systemic
humoral immunity (42). TFH-promoted responses are regulat-
ed by follicular regulatory T cell (TFR) subsets, which play a
fundamental role also in the selection of antigen-speciﬁc B cells
within the germinal center environment (43). The maintenance
of these T-cell populations does not require ongoing germinal
center responses, while depending on germinal center micro-
environment–associated signals (44). Our ﬁnding of a signif-
icant enrichment in TFH and TREG cells in FDC sarcoma sam-
ples, as compared with other mesenchymal tumors, cope with
FDC sarcomas being associated with the remnants of a germi-
nal center–type microenvironment. Among the signals over-
represented in germinal center immune networking is the
immunoregulatory PD-1 and PD-L1/2 axis, which controls the
function of germinal center T-cell subsets expressing the PD-1
receptor and the survival and differentiation of germinal center
B cells expressing PD-L2 (45). According to the higher frequen-
cy of germinal center–related T-cell populations in FDC sar-
comas, PD-1, as well as its ligands PD-L1 and PD-L2, was
signiﬁcantly higher at mRNA and protein level in FDC sarco-
mas as compared with other mesenchymal tumor histotypes
included in our study (desmoid-type ﬁbromatosis, dermatoﬁ-
brosarcoma protuberans, low-grade ﬁbromyxoid sarcomas,
Inﬂammatory myoﬁbroblastic, and solitary ﬁbrous tumors).
Interestingly, both CD274 (PD-L1) and PDCD1LG2 (PD-L2)
genes are coded in a 9p24 region which has been reported to
undergo copy number gain in FDC sarcomas (28). Within the
FDC sarcoma environment, malignant cell PD-L1/2–mediated
engagement of PD-1–expressing immune cell subsets can be
interpreted in dramatically different ways according to the
functional differentiation state of the immune cells involved
in the interaction. Indeed, while PD-1 engagement can pro-
mote the maintenance and ﬁtness of FDC sarcoma–inﬁltrating
TFH and TREG cells, it may mediate functional exhaustion of
effector cells, such as cytotoxic T cells and NK cells. Indeed,
besides ampliﬁcation of the 9p24 region, abundant PD-1
ligand expression in FDC sarcomas may represent the check-
point for T-cell responses against immunogenic mutant anti-
gens (46). The high expression of PD-L1/2 mRNA in FDC
sarcoma cases is likely responsible for the lack of correlation
with PD-1 mRNA levels, which displayed a more conspicuous
variation. Moreover, we failed to identify speciﬁc inﬁltrating
immune cell populations, among those enriched in FDC sar-
coma samples, with prominent correlation (in terms of fre-
quency) with PD-1 mRNA expression levels. This could be
interpreted in the light of the promiscuous expression of PD-1
by diverse immune cell subsets, such as TFH, TREG NK cells,
which could variably contribute to PD-1 mRNA at discrete
phases of their functional activation. These data depicting the
immune environment of FDC sarcomas should be considered
in the prospect of potential targeted immunotherapies, for
example immune checkpoint blockade, despite their inference
from molecular proﬁling. Indeed, they are well matched by
recent evidence indicating that response to antibody-based
immunotherapies may be observed even in the case of dis-
crepant target detection between protein- and mRNA-based
techniques, the latter being purportedly endowed with higher
sensitivity (47).
Overall, we demonstrated for the ﬁrst time the transcriptional
relationship of FDC sarcomas with nonmalignant FDCs and
identiﬁed the molecular programs deregulated in these rare
malignancies and allowing their differentiation from other mes-
enchymal tumors. Furthermore, we provided evidence of a pecu-
liar immunologic microenvironment associated with FDC sarco-
matous proliferation and underscored the potential relevance of
PD-1 and PD-L1/2 axis in the regulation of FDC sarcoma immune
contexture.
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